{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:22:40Z","timestamp":1780093360383,"version":"3.54.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.vph.2020.106804","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:36:18Z","timestamp":1601055378000},"page":"106804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk"],"prefix":"10.1016","volume":"135","author":[{"given":"C\u00e9cile","family":"Ingueneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hollstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Grenkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Bernard","family":"Ruidavets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Kassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Duparc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Combes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Perret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelise","family":"Genoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bobbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Steinhagen-Thiessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent O.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2020.106804_bb0005","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"FOURIER steering committee and Investigators, evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2020.106804_bb0010","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"ODYSSEY OUTCOMES committees and Investigators, alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2020.106804_bb0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","article-title":"PCSK9 inhibitors: clinical evidence and implementation","volume":"16","author":"Sabatine","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.vph.2020.106804_bb0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC scientific document group, 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2020.106804_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trsl.2015.10.004","article-title":"Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence","volume":"173","author":"Ferri","year":"2016","journal-title":"Transl. Res."},{"key":"10.1016\/j.vph.2020.106804_bb0030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-3-319-09665-0_8","article-title":"Beyond the genetics of HDL: why is HDL cholesterol inversely related to cardiovascular disease?","volume":"224","author":"Kuivenhoven","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.vph.2020.106804_bb0035","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am. J. Med."},{"key":"10.1016\/j.vph.2020.106804_bb0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.21037\/jtd.2017.12.97","article-title":"Examining the paradox of high high-density lipoprotein and elevated cardiovascular risk","volume":"10","author":"Singh","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.vph.2020.106804_bb0045","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.molmed.2011.05.013","article-title":"Biological activities of HDL subpopulations and their relevance to cardiovascular disease","volume":"17","author":"Camont","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.vph.2020.106804_bb0050","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jacc.2012.03.060","article-title":"High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis)","volume":"60","author":"Mackey","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2020.106804_bb0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.atherosclerosis.2016.01.012","article-title":"High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort","volume":"246","author":"McGarrah","year":"2016","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.vph.2020.106804_bb0060","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1038\/s41598-020-65100-2","article-title":"Serum level of HDL particles are independently associated with long-term prognosis in patients with coronary artery disease: the GENES study","volume":"10","author":"Duparc","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vph.2020.106804_bb0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2016.06.010","article-title":"Small and medium sized HDL particles are protectively associated with coronary calcification in a cross-sectional population-based sample","volume":"251","author":"Ditah","year":"2016","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.vph.2020.106804_bb0070","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/1744-9987.12792","article-title":"NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-study)","volume":"23","author":"Schettler","year":"2019","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.vph.2020.106804_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002224","article-title":"Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy","volume":"4","author":"Koren","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.vph.2020.106804_bb0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12944-016-0197-4","article-title":"Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo","volume":"15","author":"Toth","year":"2016","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.vph.2020.106804_bb0085","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.clinthera.2017.09.009","article-title":"Effects of Proprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) inhibition with Bococizumab on lipoprotein particles in Hypercholesterolemic subjects","volume":"39","author":"Wan","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.vph.2020.106804_bb0090","first-page":"115","article-title":"2016 ESC\/EAS guidelines for the Management of Dyslipidaemias","volume":"70","author":"Catapano","year":"2017","journal-title":"Rev. Esp. Cardiol. (Engl. Ed)."},{"key":"10.1016\/j.vph.2020.106804_bb0095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40256-016-0179-y","article-title":"LDL-cholesterol: standards of treatment 2016: a German perspective","volume":"16","author":"M\u00e4rz","year":"2016","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.vph.2020.106804_bb0100","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representati)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2020.106804_bb0105","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"European atherosclerosis society consensus panel, statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2020.106804_bb0110","first-page":"748","article-title":"Treatment options for statin-associated muscle symptoms","volume":"112","author":"Laufs","year":"2015","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.vph.2020.106804_bb0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.vph.2019.03.002","article-title":"Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study","volume":"116","author":"Hollstein","year":"2019","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2020.106804_bb0120","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/aje\/kwx016","article-title":"Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -Omic technologies","volume":"186","author":"W\u00fcrtz","year":"2017","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.vph.2020.106804_bb0125","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1039\/b910205a","article-title":"High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism","volume":"134","author":"Soininen","year":"2009","journal-title":"Analyst."},{"key":"10.1016\/j.vph.2020.106804_bb0130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/gm335","article-title":"Quantitative high-throughput metabolomics: a new era in epidemiology and genetics","volume":"4","author":"Ala-Korpela","year":"2012","journal-title":"Genome Med."},{"key":"10.1016\/j.vph.2020.106804_bb0135","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1161\/CIRCGENETICS.114.000216","article-title":"Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics","volume":"8","author":"Soininen","year":"2015","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.vph.2020.106804_bb0140","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2020.106804_bb0145","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am. Heart J."},{"key":"10.1016\/j.vph.2020.106804_bb0150","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.vph.2020.106804_bb0155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.atherosclerosis.2018.01.004","article-title":"PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions","volume":"269","author":"Hilvo","year":"2018","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.vph.2020.106804_bb0160","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.amjcard.2017.10.028","article-title":"Effect of Evolocumab on lipoprotein particles","volume":"121","author":"Toth","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.vph.2020.106804_bb0165","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/0003-4819-150-2-200901200-00006","article-title":"High-density lipoprotein particle size and concentration and coronary risk","volume":"150","author":"El Harchaoui","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.vph.2020.106804_bb0170","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.108.816181","article-title":"Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women","volume":"119","author":"Mora","year":"2009","journal-title":"Circulation."},{"key":"10.1016\/j.vph.2020.106804_bb0175","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1161\/CIRCULATIONAHA.118.035432","article-title":"Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence","volume":"138","author":"Aday","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.vph.2020.106804_bb0180","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2006.09.001","article-title":"Multiple risk factor intervention trial research group, lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome","volume":"195","author":"Kuller","year":"2007","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.vph.2020.106804_bb0185","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002295","article-title":"High-density lipoprotein subclasses and noncardiovascular, noncancer chronic inflammatory-related events versus cardiovascular events: the multi-ethnic study of atherosclerosis","volume":"4","author":"Duprez","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.vph.2020.106804_bb0190","doi-asserted-by":"crossref","first-page":"46642","DOI":"10.1038\/srep46642","article-title":"Serum concentration of HDL particles predicts mortality in acute heart failure patients","volume":"7","author":"Poto\u010dnjak","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vph.2020.106804_bb0195","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002977","article-title":"Concentration of smaller high-density lipoprotein particle (HDL-P) is inversely correlated with carotid intima media thickening after confounder adjustment: the multi ethnic study of atherosclerosis (MESA)","volume":"5","author":"Kim","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.vph.2020.106804_bb0200","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/CIRCULATIONAHA.105.565135","article-title":"Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial","volume":"113","author":"Otvos","year":"2006","journal-title":"Circulation."},{"key":"10.1016\/j.vph.2020.106804_bb0205","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0005-2760(85)90142-0","article-title":"Triacylglycerol increase in plasma very low density lipoproteins in cyclophosphamide-treated rabbit: relationship with cholesteryl ester transfer activity","volume":"836","author":"Loudet","year":"1985","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.vph.2020.106804_bb0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-016-0428-z","article-title":"Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases","volume":"15","author":"Girona","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.vph.2020.106804_bb0215","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41431-018-0301-5","article-title":"Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile","volume":"27","author":"Blauw","year":"2019","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.vph.2020.106804_bb0220","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1016\/S0021-9258(19)89234-7","article-title":"Conversion of human plasma high density lipoprotein-2 to high density lipoprotein-3. Roles of neutral lipid exchange and triglyceride lipases","volume":"261","author":"Deckelbaum","year":"1986","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2020.106804_bb0225","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1194\/jlr.M500187-JLR200","article-title":"Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux","volume":"46","author":"Asztalos","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.vph.2020.106804_bb0230","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/CIRCRESAHA.116.305485","article-title":"HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export","volume":"116","author":"Du","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2020.106804_bb0235","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1185\/030079907X188062","article-title":"Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia","volume":"23","author":"Kalogirou","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.vph.2020.106804_bb0240","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1194\/jlr.M800302-JLR200","article-title":"Origins of intestinal ABCA1-mediated HDL-cholesterol","volume":"49","author":"Field","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.vph.2020.106804_bb0245","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/ncpcardio0500","article-title":"Antiatherogenic small, dense HDL--guardian angel of the arterial wall?","volume":"3","author":"Kontush","year":"2006","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189120303098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189120303098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:19:35Z","timestamp":1761527975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189120303098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":49,"alternative-id":["S1537189120303098"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2020.106804","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2020.106804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106804"}}